Browse the evidence

Environmental-level factors, such as the food environment and socioeconomic status, interact with individual-level biological factors to drive obesity, and interventions focusing solely on the individual are suboptimal.

To manage weight effectively, you need to address both your personal habits and your environment. This might mean seeking out healthier food options, advocating for policy changes, and understanding how your biology interacts with your surroundings.

Obesity is a chronic, progressive, relapsing, and treatable multi-factorial neurobehavioral disease, not just a lifestyle choice.

Understand that obesity is a disease with biological drivers, not just a failure of will. This reduces self-blame and opens the door to effective medical and lifestyle interventions.

SGLT2 inhibitors provide consistent cardiovascular benefits (reduced mortality and morbidity) across all BMI classes in heart failure, with no mediating effect of obesity on their efficacy.

If you have heart failure, SGLT2 inhibitors (like Dapagliflozin or Empagliflozin) are a standard, highly effective treatment that works regardless of your weight. They reduce the risk of hospitalization and death. Discuss starting these with your doctor if you are not already on them.

Obesity is fundamentally a chronic metabolic disease characterized by disturbances in energy homeostasis and excessive fat accumulation, driven by a complex interplay of genetic, epigenetic, biological, psychological, and environmental factors.

Understand that obesity is a complex chronic disease, not a moral failing. Effective management requires addressing biological, genetic, and environmental factors, often necessitating medical interventions alongside lifestyle changes.

Genetic variants, particularly in the MC4R, FTO, and LEP/LEPR genes, significantly influence susceptibility to obesity, affecting appetite regulation, energy expenditure, and fat storage.

Genetics play a significant role in obesity risk. If you have a family history of obesity, you may have a higher predisposition. However, this does not mean weight management is impossible; tailored medical and lifestyle strategies can be highly effective.

BMI is an insufficient diagnostic tool for obesity because it fails to differentiate between fat mass and lean body mass, leading to misclassification.

Do not rely solely on BMI to determine your health status. It fails to distinguish between muscle and fat. Ask your doctor for more precise assessments like waist circumference or body composition analysis to get a true picture of your metabolic risk.

Higher genetically predicted lifelong BMI causally increases all-cause mortality, with the effect substantially mediated through diabetes.

In this population, higher lifelong BMI significantly increases the risk of premature death, largely by increasing the risk of diabetes. Managing weight and blood sugar are critical for longevity.

Higher genetically predicted BMI causally increases the risk of renal, acute diabetic crisis, and infective deaths.

Higher BMI is strongly linked to death from kidney disease, severe diabetic episodes, and infections. Preventing these outcomes requires addressing underlying metabolic health.

Energy expenditure can be increased through specific physiological mechanisms independent of physical activity, including UCP1-dependent thermogenesis in brown/beige fat, futile cycling of substrates (creatine, glucose, lipids), and ion pumping (Na+/K+-ATPase, SERCA).

Your body burns calories through several active processes beyond just moving around. These include generating heat in fat tissue (thermogenesis), running 'futile' metabolic cycles that burn energy as heat, and maintaining electrical gradients in cells. While you can't easily control these directly, understanding them helps explain why some medications work better than others. Future treatments may target these specific pathways to help you burn more calories passively.

Semaglutide provides robust cardiovascular risk reduction (MACE) in patients with Type 2 Diabetes and established cardiovascular disease, independent of glycemic control improvements.

If you have obesity and established heart disease, semaglutide (2.4mg weekly) significantly reduces your risk of major adverse cardiovascular events (MACE), even if you do not have diabetes. This benefit is driven by weight loss and cardiometabolic improvement, not just blood sugar control.

Insulin resistance is the primary driver of diabetic dyslipidemia, causing elevated triglycerides, low HDL-C, and small dense LDL particles through increased hepatic VLDL secretion and altered lipoprotein metabolism.

If you have Type 2 Diabetes or Insulin Resistance, your high triglycerides and low HDL are likely driven by your body's resistance to insulin, not just what you eat. Focus on improving insulin sensitivity through weight loss, exercise, and medical management, as this addresses the root cause of the lipid abnormalities.

Intensive lifestyle modification in type 2 diabetes yields only transient weight loss and fails to reduce cardiovascular mortality or clinically relevant endpoints compared to conventional care.

Intensive lifestyle programs for type 2 diabetes can help with short-term weight loss, but they do not prevent heart attacks or death in the long run. Do not feel pressured to achieve perfect lifestyle changes if they do not improve your cardiovascular outcomes, as the evidence for mortality benefit is lacking. Focus on manageable habits rather than extreme regimens.

Heart disease and stroke remain the leading causes of death globally, with significant disparities in prevalence and mortality across different racial and ethnic groups, necessitating targeted public health interventions to address structural racism and health equity.

Focus on managing key risk factors like blood pressure, cholesterol, and blood sugar, while being aware of and addressing potential systemic barriers to healthcare access.

Obesity drives insulin resistance and type 2 diabetes through the accumulation of free fatty acids and pro-inflammatory cytokines in non-adipose tissues, which activate kinases (PKC, JNK, IKKβ) that inhibit insulin receptor signaling.

If you have obesity, your risk for type 2 diabetes is significantly higher due to biological changes in your fat tissue and blood. This isn't just about 'eating less'; it's about how your body processes energy. Addressing obesity through sustainable lifestyle changes can mitigate these specific biological risks.

A cumulative deficit frailty index, constructed from 26 non-traditional health deficits, is a stronger predictor of cardiovascular events and mortality than traditional risk scores (like Framingham) and provides incremental prognostic value independent of those traditional factors.

If you are over 65 or have heart disease risk factors, ask your doctor to assess your 'frailty' using a deficit accumulation model (checking for symptoms, lab abnormalities, and functional limitations), not just standard cholesterol and blood pressure numbers. This assessment predicts heart attacks and death more accurately than traditional scores and can help prioritize preventive care.

Body weight regulation is not governed by a single fixed set-point, but rather by a dynamic equilibrium where energy expenditure passively adjusts to match intake, creating a 'zone of indifference' bounded by upper and lower intervention points.

Do not assume your body has a rigid 'set point' that fights against you. Your weight settles at a level where your energy expenditure matches your intake. If your environment changes (e.g., more food, less activity), your weight will drift until your expenditure rises to match the new intake. Understanding this passive feedback helps explain why small, sustained environmental changes lead to gradual weight gain over years.

Obesity, particularly visceral adiposity, significantly increases the risk of esophageal adenocarcinoma (EAC) through both mechanical factors (increased reflux) and biological mechanisms (adipokine secretion and systemic inflammation).

Maintaining a healthy weight, particularly reducing visceral fat, is a critical strategy for lowering the risk of esophageal adenocarcinoma. This involves not just weight loss but also managing metabolic health through diet and physical activity, as these factors influence the hormonal and inflammatory environment that drives cancer development.

Alternate-day fasting does not produce superior weight loss, weight maintenance, or cardioprotection compared to daily calorie restriction in metabolically healthy obese adults.

If you are obese and metabolically healthy, alternate-day fasting is not a magic bullet for better weight loss or heart health compared to simply eating less every day. It is equally effective for weight loss but may be harder to stick to long-term, as evidenced by higher dropout rates. Choose the diet you can sustain consistently.

Bariatric surgery (specifically Roux-en-Y gastric bypass) produces the largest and most durable weight loss among current treatments, serving as a benchmark for efficacy, though individual response varies significantly.

If lifestyle and medications fail, bariatric surgery (like RYGB) is the most effective option for significant, sustained weight loss, averaging over 30% loss. It is considered the benchmark for efficacy, though it requires lifelong medical follow-up.

Bariatric surgery provides the most durable and dramatic weight loss among available treatments, significantly reducing long-term mortality and diabetes incidence.

For severe obesity, surgery is the most effective long-term solution, offering the best chance for durable weight loss and reduced health risks like diabetes and mortality. Consider it if other methods have failed or if your health is at significant risk.

Intermittent energy restriction (IER) diets (time-restricted eating, alternate-day fasting, and 5:2 diet) do not produce superior improvements in body weight, fat mass, or cardiometabolic risk markers compared to continuous energy restriction (CER) when total energy intake is matched.

If your goal is weight loss or better metabolic health, you do not need to adopt a complex intermittent fasting schedule. A standard daily calorie restriction diet is equally effective. Focus on maintaining a consistent caloric deficit rather than restricting your eating window, unless you personally prefer the structure of fasting.

During the refeeding phase after caloric restriction, initial rapid weight regain is predominantly water retention, while actual fat and protein storage occurs more slowly and may be masked by continued water loss in later recovery stages.

When you start eating more after a diet, you will see the scale jump up quickly. Most of this is water, not fat. Later, you might see the scale stall even while you are eating in a surplus, because your body is rebuilding tissue while losing water. Trust the process, not just the scale.

Empagliflozin (10-25 mg daily) reduces the risk of major adverse cardiovascular events (MACE), cardiovascular death, all-cause mortality, and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk.

If you have type 2 diabetes and established heart disease, adding empagliflozin (10-25 mg daily) to your standard care significantly lowers your risk of heart attack, stroke, heart failure hospitalization, and death from any cause. While you may experience an increased risk of genital infections, the cardiovascular benefits are substantial and well-documented in this large trial.

Combined estrogen plus progestin therapy significantly reduces the risk of hip fractures and colorectal cancer in postmenopausal women.

While estrogen plus progestin therapy does reduce the risk of hip fractures and colorectal cancer, these benefits are not sufficient to justify the use of the therapy for primary prevention of chronic diseases due to the increased risks of heart disease, stroke, blood clots, and breast cancer.